TITLE:
Post-Quinine Bilious Hemoglobin Fever in an 8-Year-Old Child Monitored for Severe Malaria at the Yalosase Health Center, Isangi, DR Congo
AUTHORS:
Dieudonné Lobela Bumba, Issa Yakusu Issa, Bruce Wembolua Shinga, Muyobela Kampunzu, Gilbert Bokungu Isongibi, Francy Baelongandi Folo, Jacques Ossinga Bassandja
KEYWORDS:
Bilious Hemoglobin Fever, Severe Malaria, Quinine, Isangi
JOURNAL NAME:
Advances in Infectious Diseases,
Vol.11 No.1,
February
1,
2021
ABSTRACT: It has been known since March 2013 that Artesunate is considered the gold standard treatment for severe malaria [1] [2] [3]. However, in our regions, the drug of choice available to treat patients with severe malaria remains quinine until today. However, frequent and sequential use of quinine is associated with the occurrence of hemoglobinuria [2]. We report a probable case of bilious hemoglobin fever (BHF) in an 8-year-old child. This was an 8-year-old child with a history of frequent and recent treatment with quinine, received in consultation for coca-cola urine emission with rapid diagnostic test (RDT) positive. In search of a particular terrain, the retroviral and syphilitic serologies were negative. Considering the context, the diagnosis of post-quinine hemoglobin bilious fever (BHF) was retained and the patient had progressed well after administration of artemisinin and its derivatives. The child was followed, on an outpatient basis, without any sequelae. It would therefore be prudent for the time being to avoid them in prophylaxis and self-medication.